JCO Precision Oncology : Impact Factor & More
eISSN: 2473-4284pISSN: 2473-4284
Share this on:
Key Metrics
CiteScore 
6.6
Eigenfactor
0.005 - 0.01
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.98
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on JCO Precision Oncology
JCO Precision Oncology Journal Specifications
Indexed in the following public directories
Web of Science 
SJR
| Overview | |
| Publisher | LIPPINCOTT WILLIAMS & WILKINS |
| Language | English |
| Frequency | Continuous publication |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2017 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in JCO Precision Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in JCO Precision Oncology
Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non\u2013Small Cell Lung Cancer
- 14 May 2026
- JCO Precision Oncology
Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer
- 14 May 2026
- JCO Precision Oncology
Genomics of MTAP Loss in >500,000 Solid Tumor Specimens Profiled Using Comprehensive Genomic Profiling Platforms
- 14 May 2026
- JCO Precision Oncology
Cell-Free DNA Uncovered Tumor Heterogeneity and Informed Targeted Therapy in a Pediatric Rhabdomyosarcoma
- 11 May 2026
- JCO Precision Oncology
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial
- 11 May 2026
- JCO Precision Oncology
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0
- 11 May 2026
- JCO Precision Oncology
Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non\u2013Small Cell Lung Cancer
- 14 May 2026
- JCO Precision Oncology
Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer
- 14 May 2026
- JCO Precision Oncology
Genomics of MTAP Loss in >500,000 Solid Tumor Specimens Profiled Using Comprehensive Genomic Profiling Platforms
- 14 May 2026
- JCO Precision Oncology
Cell-Free DNA Uncovered Tumor Heterogeneity and Informed Targeted Therapy in a Pediatric Rhabdomyosarcoma
- 11 May 2026
- JCO Precision Oncology
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial
- 11 May 2026
- JCO Precision Oncology
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0
- 11 May 2026
- JCO Precision Oncology
FAQs on JCO Precision Oncology
How long has JCO Precision Oncology been actively publishing? 
What is the publishing frequency of JCO Precision Oncology?
How many articles did JCO Precision Oncology publish last year?
What is the eISSN & pISSN for JCO Precision Oncology?
What is Citescore for JCO Precision Oncology?
What is SNIP score for JCO Precision Oncology?
What is the SJR for JCO Precision Oncology?
Who is the publisher of JCO Precision Oncology?
